P21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis

Citation
Km. Ropponen et al., P21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis, BR J CANC, 81(1), 1999, pp. 133-140
Citations number
44
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
BRITISH JOURNAL OF CANCER
ISSN journal
00070920 → ACNP
Volume
81
Issue
1
Year of publication
1999
Pages
133 - 140
Database
ISI
SICI code
0007-0920(199909)81:1<133:PEIHCC>2.0.ZU;2-B
Abstract
p21/WAF1 expression was studied in a series of 162 colorectal carcinoma pat ients and its relation to p53- and activator protein (AP)-2 expressions and to stage as well as survival was assessed, p21 expression was moderate or intense in 33% of the tumours, and 53% of the tumours had moderate or stron g p53 staining intensity. Eighty-nine percent of the tumours showed a weak cytoplasmic AP-2 signal. As expected, p21 and p53 stainings were inversely related to each other(P< 0.001). There was a significant positive associati on between p21 and AP-2 expression levels (P= 0.01). p21 intensity and perc entage were higher in Dukes' A and B stages (P < 0.001), The cancer-related survival and recurrence-free survival (RFS) rates were significantly lower among patients with a low signal for p21 (P < 0.001) and low p21 percentag e in tumour epithelium (P < 0.001). High p53 staining intensity in tumour e pithelium predicted poor survival (P = 0.01) and RFS (P = 0.003). In the mu ltivariate analysis, p21 percentage distribution independently predicted ca ncer-related survival in all cases, and p21 expression intensity in T1-4/N0 -3/M0 and T1-3/N0/M0 cases, p21 percentage distribution was an independent predictor of RFS in ail and T1-3/ N0/M0 cases. AP-2 staining did not reach any prognostic significance. These results suggest that the immunohistochem ical detection of cyclin-dependent kinase inhibitor p21 could be used to pr edict more precisely the outcome of colorectal cancer patients.